Zions Bancorporation’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | $8.93M | Buy |
50,232
+20,560
| +69% | +$3.78M | 0.56% | 25 |
|
|
2024
Q3 | $5.86M | Buy |
29,672
+813
| +3% | +$152K | 0.43% | 43 |
|
|
2024
Q2 | $4.95M | Sell |
28,859
-3,978
| -12% | -$659K | 0.4% | 49 |
|
|
2024
Q1 | $5.98M | Sell |
32,837
-18,667
| -36% | -$3.22M | 0.44% | 40 |
|
|
2023
Q4 | $7.98M | Buy |
51,504
+7,338
| +17% | +$1.07M | 0.55% | 26 |
|
|
2023
Q3 | $6.58M | Buy |
44,166
+2,529
| +6% | +$371K | 0.58% | 24 |
|
|
2023
Q2 | $5.61M | Sell |
41,637
-7,418
| -15% | -$1.09M | 0.47% | 32 |
|
|
2023
Q1 | $7.82M | Buy |
49,055
+6,921
| +16% | +$1.06M | 0.67% | 20 |
|
|
2022
Q4 | $6.81M | Buy |
42,134
+3,379
| +9% | +$518K | 0.54% | 25 |
|
|
2022
Q3 | $5.2M | Sell |
38,755
-3,027
| -7% | -$434K | 0.54% | 19 |
|
|
2022
Q2 | $6.4M | Sell |
41,782
-13,872
| -25% | -$2.12M | 0.64% | 18 |
|
|
2022
Q1 | $9.02M | Buy |
55,654
+5,763
| +12% | +$837K | 0.81% | 11 |
|
|
2021
Q4 | $6.75M | Buy |
49,891
+3,176
| +7% | +$375K | 0.6% | 12 |
|
|
2021
Q3 | $5.04M | Buy |
46,715
+636
| +1% | +$72.7K | 0.52% | 16 |
|
|
2021
Q2 | $5.19M | Buy |
46,079
+6,933
| +18% | +$781K | 0.52% | 14 |
|
|
2021
Q1 | $4.24M | Buy |
39,146
+7,701
| +24% | +$824K | 0.48% | 16 |
|
|
2020
Q4 | $3.37M | Sell |
31,445
-441
| -1% | -$42.4K | 0.42% | 18 |
|
|
2020
Q3 | $2.79M | Sell |
31,886
-3,451
| -10% | -$325K | 0.4% | 21 |
|
|
2020
Q2 | $3.47M | Sell |
35,337
-1,967
| -5% | -$173K | 0.5% | 17 |
|
|
2020
Q1 | $2.84M | Buy |
37,304
+5,613
| +18% | +$478K | 0.5% | 18 |
|
|
2019
Q4 | $2.81M | Sell |
31,691
-3,800
| -11% | -$315K | 0.4% | 21 |
|
|
2019
Q3 | $2.69M | Buy |
35,491
+3,788
| +12% | +$260K | 0.39% | 21 |
|
|
2019
Q2 | $2.31M | Buy |
31,703
+2,889
| +10% | +$227K | 0.34% | 27 |
|
|
2019
Q1 | $2.32M | Buy |
28,814
+1,995
| +7% | +$163K | 0.38% | 28 |
|
|
2018
Q4 | $2.47M | Buy |
26,819
+8,096
| +43% | +$712K | 1.81% | 6 |
|
|
2018
Q3 | $1.77M | Buy |
18,723
+625
| +3% | +$59.3K | 0.42% | 27 |
|
|
2018
Q2 | $1.68M | Buy |
+18,098
| New | +$1.77M | 1.15% | 15 |
|
|
2017
Q4 | – | Sell |
-39,013
| Closed | -$3.47M | – | 588 |
|
|
2017
Q3 | $3.47M | Buy |
39,013
+20,452
| +110% | +$1.56M | 0.5% | 27 |
|
|
2017
Q2 | $1.35M | Buy |
18,561
+9,841
| +113% | +$662K | 0.23% | 56 |
|
|
2017
Q1 | $569K | Buy |
8,720
+542
| +7% | +$34.1K | 0.11% | 81 |
|
|
2016
Q4 | $512K | Buy |
8,178
+117
| +1% | +$7.14K | 0.09% | 85 |
|
|
2016
Q3 | $506K | Buy |
8,061
+7
| +0.1% | +$453 | 0.1% | 85 |
|
|
2016
Q2 | $502K | Sell |
8,054
-217
| -3% | -$13.2K | 0.09% | 89 |
|
|
2016
Q1 | $478K | Buy |
8,271
+34
| +0.4% | +$1.9K | 0.09% | 88 |
|
|
2015
Q4 | $479K | Sell |
8,237
-604
| -7% | -$34.8K | 0.08% | 84 |
|
|
2015
Q3 | $495K | Sell |
8,841
-6,038
| -41% | -$393K | 0.09% | 82 |
|
|
2015
Q2 | $1M | Buy |
14,879
+10,110
| +212% | +$660K | 0.16% | 81 |
|
|
2015
Q1 | $279K | Buy |
+4,769
| New | +$288K | 0.05% | 114 |
|
Other funds holding ABBV
Zions Bancorporation's ABBV Position: Q4 2024 in Review
Zions Bancorporation increased its AbbVie (ABBV) stake by 69% in Q4 2024, buying an estimated $3.78M and bringing the position to 50,232 shares worth $8.93M. The position accounts for 0.56% of the portfolio, ranked #25.
Zions Bancorporation first reported a position in ABBV in Q1 2015 and has held it in 38 quarters since. The position peaked at $9.02M in Q1 2022. 3,745 funds tracked by Wall St. Rank hold ABBV as of Q4 2024.
- Zions Bancorporation held 50,232 shares of AbbVie worth $8.93M as of Q4 2024.
- Zions Bancorporation bought 20,560 AbbVie shares in Q4 2024, an estimated $3.78M.
- AbbVie made up 0.56% of Zions Bancorporation's portfolio in Q4 2024, its #25 holding.
- Zions Bancorporation first reported a position in AbbVie in Q1 2015 and has held it in 38 quarters since.
- Zions Bancorporation's AbbVie position peaked at $9.02M in Q1 2022.
- 3,745 funds tracked by Wall St. Rank held AbbVie as of Q4 2024.
Based on Zions Bancorporation's 13F filing for Q4 2024, filed 11 Feb 2025.